

Invest in UK MedTech

Device, Diagnostics and Digital Healthcare

The UK is a prime location to research, develop and evaluate MedTech products and services in the National Health Service (NHS), one of the world's best healthcare systems. The UK is a test bed for your global market development supported by well-established, pragmatic regulatory and guidance agencies.

 Dedicated infrastructure for **MedTech research**, development and evaluation with support across the entire product innovation pathway

 **National agencies** working together to improve the NHS innovation pipeline with active horizon scanning and adoption support for streamlined market entry

 Significant **commercial sector** within connected clusters across the UK offering wide range of affordable location options to suit company needs, large and small

 Government commitment to **MedTech innovation** underpinned by sustained partnership working with industry

Supported Pipeline:

85% MedTech studies close to time and target; 150 MedTech companies supported by national innovation and adoption organisations (2018/19)

Pragmatic Agencies:

National Institute for Health and Care Excellence (NICE) had positive recommendation rate of over 80% (2013/19)

Significant Sector:


More than 3,800 MedTech businesses operate in the UK including innovative SMEs and significant supply chain; Global Top 30 MedTech businesses employ nearly 1 in 5 people in the UK MedTech sector; UK MedTech sector employment is ranked 4th in the world

NHS Innovation:

Bradford Teaching Hospitals NHS Foundation Trust is collaborating with GE Healthcare to build an AI driven command centre - the first of its kind in Europe (2018)

“We are delighted that NHS England has chosen to fund and help to encourage the widespread adoption of the HeartFlow Analysis. We look forward with NHS England to improve efficiency and the patient experience.”

**John H. Stevens, MD,
President and CEO, HeartFlow**



NHS supports the introduction of HeartFlow's technology

US-based HeartFlow, Inc. is a digital health company redefining the way heart disease is diagnosed and treated. Its non-invasive HeartFlow FFRct Analysis leverages deep learning and highly trained analysts to create a personalized 3D model of the heart, enabling clinicians to better evaluate the impact of a blockage and determine the best treatment for patients.

Heartflow has benefitted from the UK's innovation infrastructure and support to introduce its technology to the National Health Service (NHS) and to patients.

The National Institute for Health and Clinical Excellence (NICE) was among the first organisations in the world to perform a complete health technology assessment of HeartFlow. Following this the technology was selected by the Accelerated Access Collaborative (AAC) as a 'Rapid Uptake Product'. The AAC brings together industry, government, regulators, patients and the NHS to deliver the best health innovations to patients faster than ever. As a 'Rapid Uptake Product', HeartFlow's technology received funding and bespoke support for widespread adoption in the NHS, as well as regional support via the national Academic Health Science Networks, making a real difference to patient care and outcomes.

150 MEDTECH COMPANIES

supported by national innovation and adoption organisations (2018/19)

MORE THAN 3,800 MEDTECH

operate in the **UK including innovative SMEs** and significant supply chain

GLOBAL TOP 30 MEDTECH

businesses employ nearly **1 in 5 people** in the UK MedTech sector

UK MEDTECH SECTOR

employment is ranked **4th in the world**



**Department for
International Trade**

How we can help

On your investment journey will we connect you into a community of support. We are committed to helping you make the most of the opportunities to use the UK as your gateway to the world.

Contact us today:

[**lifescience@trade.gov.uk**](mailto:lifescience@trade.gov.uk)